NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
February 10, 2026 — STEMart launches In Vivo Mouse Micronucleus Test for medical device genotoxicity assessment, ensuring compliance with ISO 10993-3 and OECD guidelines to enhance patient safety.
February 10, 2026 — New Jersey Brain & Spine ranks among the Top 3 neurosurgical practices in the US, recognized for its concentration of Castle Connolly Top Doctors and comprehensive care for brain & spine conditions.
February 10, 2026 — Friendly Recovery Center releases educational blog on depression headaches, linking emotional distress to physical pain. Learn about symptoms and their mental health intensive outpatient program.
February 9, 2026 — LIXTE Biotechnology's LB-100 compound enhances cancer treatment effectiveness by inhibiting PP2A, potentially improving immunotherapy and chemotherapy outcomes for patients with resistant cancers.
February 9, 2026 — LIXTE Biotechnology acquires Liora Technologies and its LiGHT proton therapy system, enhancing cancer treatment with LB-100 synergy. Read the latest updates on this strategic move.
February 9, 2026 — Oragenics advances ONP-002, an intranasal neurosteroid for concussion treatment, toward Phase 2 trials in 2026. Learn about this potential first-in-class therapy and its impact on neurological care.
February 9, 2026 — Families Rights Matter2 movement advocates for HIPAA reform to help families during mental health emergencies. Learn about the petition on change.org and why current rules block critical information.
February 9, 2026 — DCS Rescue releases a guide on urgent vs emergent moves in confined space rescue. Learn the critical distinction for patient extraction & responder safety in high-pressure emergency scenarios.
February 9, 2026 — New Horizon Medical Solutions partners with Soring to distribute ultrasonic wound debridement devices for chronic and acute wound treatment, enhancing patient outcomes through advanced technology.
February 9, 2026 — Creative Diagnostics launches AI-powered infectious disease drug discovery platform combining AI with high-performance computing to accelerate antiviral research and combat antimicrobial resistance.
February 6, 2026 — LIXTE Biotechnology's LB-100 compound enhances cancer immunotherapy & chemotherapy effectiveness by targeting PP2A enzyme. Clinical trials show promise for ovarian & colon cancers.
February 6, 2026 — LIXTE Biotechnology advances cancer treatment with LB-100, a PP2A inhibitor designed to enhance existing immunotherapy and chemotherapy, targeting resistance in clinical trials for ovarian and colon cancers.
February 6, 2026 — Soligenix announces positive Phase 2 results for SGX945 in Behçet's disease, a rare inflammatory condition. The novel therapy shows promise as a safe, immune-modulating treatment for underserved patients.
February 6, 2026 — Phase III trial shows loberamisal, a novel neuroprotective drug, improves stroke recovery with 69% excellent outcomes. Presented at American Stroke Association conference.
February 6, 2026 — New I-ACQUIRE therapy improves arm function in toddlers after stroke. High-dose, home-based treatment shows lasting benefits vs. usual care in a major clinical trial.
February 6, 2026 — Lionheart Health partners with Rejuvant in XPRIZE Healthspan Semi-Finals, integrating CaAKG supplements with multi-modal healthspan optimization including personalized nutrition and bioelectric exercise.
February 6, 2026 — New light-activated therapy targets microscopic brain cancer cells after surgery. Preclinical study shows promise for eliminating residual cancer tissue that surgeons cannot see during tumor removal.
February 6, 2026 — Albrechtsen & Fanelli Orthodontics now offers MARPE treatment in Utah, a non-surgical solution for narrow palates in teens and adults. Learn about this advanced orthodontic care.
February 6, 2026 — Healthcare pros endorse Deeply Unimportant podcast for sleep aid, using cognitive shuffling to calm racing thoughts in ADHD/OCD. Hosted by ex-newscaster Dallas Kachan.
February 5, 2026 — LIXTE Biotechnology enhances cancer therapies by targeting treatment resistance with LB-100 compound. Clinical trials show promise for ovarian, colon & sarcoma cancers. Learn about this innovative approach to improving existing treatments.